Cost and savings information coming soon

Why you may be prescribed HOVILPRI

HOVILPRI may be appropriate for adults who have:

Weakened immune systems

And

And

Oral herpes (HSV-1) or genital herpes (HSV-2) that does not get better with initial treatment prescribed by their healthcare provider

Photo of a doctor talking with a patient about treatment (not an actual patient or doctor)
Photo of a doctor talking with a patient about treatment (not an actual patient or doctor)

Not actual patient and doctor.

How to take HOVILPRI

HOVILPRI is taken by mouth once a day, with or without food.

To start, you will take 400 mg (4 tablets) by mouth on the first day of your treatment. Then you will take 100 mg (1 tablet) every day after that until your sores, also known as lesions, from HSV infection have healed.

If you miss a dose of HOVILPRI, take it as soon as you remember. If you don’t remember until the next day’s scheduled dose, take 2 tablets at that time.

Before starting treatment

Tell your healthcare provider about all the medicines you take, including stomach acid–reducing medicines (proton pump inhibitors, such as esomeprazole or rabeprazole, and H2-receptor blockers, such as famotidine and ranitidine) and antacids used for heartburn or indigestion. Some of these medicines may need to be avoided, have their dosage altered, or taken at a different time than HOVILPRI.

How was HOVILPRI studied?

The HOVILPRI clinical study included patients who had:

Portrait of a woman, representing a patient in the HOVILPRI clinical study (not an actual patient)
Not actual patient.
  • Weakened immune systems due to factors such as HIV infection, a hematopoietic cell or solid organ transplant, or long-term treatment with certain medicines that weaken the immune system
  • Lesions due to HSV infection that did not improve after at least 7 days of treatment with a first-line class of HSV medications called nucleoside analogues, which include acyclovir, valacyclovir, and famciclovir
Portrait of a woman, representing a patient in the HOVILPRI clinical study (not an actual patient)
Not actual patient.

Eligible patients were randomly placed in 1 of 2 treatment groups

HOVILPRI treatment group

Patients received a starting dose of 400 mg on Day 1, followed by 100 mg taken by mouth once daily starting on Day 2.

Investigator’s choice of treatment

The study healthcare provider selected the treatment that the patient would receive from the following options: intravenous (IV) foscarnet, IV or topical cidofovir, or topical imiquimod.

How was the effectiveness of HOVILPRI measured in the clinical study?

The main goal of the study was to determine complete healing of HSV lesions, and no new lesions, up to Day 28 of treatment.

Results with HOVILPRI

Nearly twice as many patients who received HOVILPRI had their HSV lesions completely heal compared with patients who received other treatments chosen by their study healthcare provider.

Complete lesion healing up to Day 28

HOVILPRI

32 of 51 patients

Other treatments

17 of 50 patients

Possible side effects of HOVILPRI

Before starting treatment, tell your healthcare provider about:

  • All prescription and over-the-counter medicines, vitamins, or herbal supplements you take, especially if you take medicines used to lower stomach acid
  • Any other medical conditions you may have
  • If you are pregnant, planning to 
become pregnant, or breastfeeding

The most common side effects of HOVILPRI include:

  • Headache (6%)
Photo of a doctor talking with a patient about treatment (not an actual patient or doctor)
Not actual patient and doctor.

Talk with your healthcare provider to see if HOVILPRI may be right for you.

For complete safety information, read the Prescribing Information.

Frequently asked questions